Barrow D L, Mizuno J, Tindall G T
Department of Surgery (Neurosurgery), Emory University School of Medicine, Atlanta, Georgia.
J Neurosurg. 1988 Apr;68(4):554-8. doi: 10.3171/jns.1988.68.4.0554.
The authors have reviewed the results of transsphenoidal microsurgical management in 69 patients with prolactin-secreting pituitary adenomas who had preoperative serum prolactin levels over 200 ng/ml. The patients were divided into three groups based on their preoperative serum prolactin levels: over 200 to 500 ng/ml (Group A); over 500 to 1000 ng/ml (Group B); and over 1000 ng/ml (Group C). The percentage of successful treatment ("control rate") was 68%, 30%, and 14%, respectively, in these three groups of patients. Based on these results, the authors offer guidelines for the management of patients with prolactin-secreting pituitary adenomas associated with exceptionally high serum prolactin levels. The surgical control rate of 68% in Group A seems to justify surgery for these patients, while primary medical care with bromocriptine is recommended for most patients with serum prolactin levels over 500 ng/ml.
作者回顾了69例术前血清催乳素水平超过200 ng/ml的分泌催乳素垂体腺瘤患者经蝶窦显微手术治疗的结果。根据术前血清催乳素水平将患者分为三组:超过200至500 ng/ml(A组);超过500至1000 ng/ml(B组);超过1000 ng/ml(C组)。这三组患者的成功治疗百分比(“控制率”)分别为68%、30%和14%。基于这些结果,作者为血清催乳素水平异常高的分泌催乳素垂体腺瘤患者的管理提供了指导方针。A组68%的手术控制率似乎证明这些患者进行手术是合理的,而对于大多数血清催乳素水平超过500 ng/ml的患者,建议首选溴隐亭进行药物治疗。